Status:
COMPLETED
Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
Lead Sponsor:
Zeria Pharmaceutical
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
PHASE2
Brief Summary
To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study
Eligibility Criteria
Inclusion
- Subjects with unresectable locally advanced or metastatic pancreatic cancer
- KPS \> 70%
- Life expectancy of at least 3 months
Exclusion
- received previous chemotherapy for the current indication
- received previous radiotherapy for the current indication
- Currently receiving chemotherapy
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00288925
Start Date
September 1 2005
Last Update
June 1 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Free Hospital
London, United Kingdom, NW3 2QG